[1]林 芳,任 阳,李 亚.缺血性卒中不同亚型患者血清CXCL12水平急性期动态观察[J].现代检验医学杂志,2017,32(05):48-51.[doi:10.3969/j.issn.1671-7414.2017.05.013]
　LIN Fang,REN Yang,LI Ya.Dynamic Observation of Serum CXCL-12 in Patients with Different Subtypes of Acute Ischemic Stroke[J].Journal of Modern Laboratory Medicine,2017,32(05):48-51.[doi:10.3969/j.issn.1671-7414.2017.05.013]
点击复制

缺血性卒中不同亚型患者血清CXCL12水平急性期动态观察()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
48-51
栏目:
论著
出版日期:
2017-11-02

文章信息/Info

Title:
Dynamic Observation of Serum CXCL-12 in Patients with Different Subtypes of Acute Ischemic Stroke
文章编号:
1671-7414(2017)05-048-04
作者:
林 芳a,任 阳b,李 亚b
延安大学附属医院a.老年病科; b.内分泌科,陕西延安 716000
Author(s):
LIN Fanga,REN Yangb,LI Yab
a.Department of Geriatrics; b.Department of Endocrinology,Affiliated Hospital of Yan'an University,Shaanxi Yan'an716000,China
关键词:
血清趋化因子配体-12;  急性缺血性卒中;  动态变化;  预后
分类号:
R743.3; R392.11
DOI:
10.3969/j.issn.1671-7414.2017.05.013
文献标志码:
A
摘要:
目的 观察缺血性卒中不同亚型患者急性期血清趋化因子配体12(CXCL-12)水平的动态变化。方法 选择2014年1月～2016年6月在延安大学附属医院老年病科治疗的141例急性缺血性卒中患者,按照TOAST分型方法分为大动脉粥样硬化性卒中(LAA)52例,小动脉闭塞性脑卒中或腔隙性脑卒中(SAO)组54例和心源性脑栓塞(CE)组35例,另外选取60例同期门诊健康体检成人设置对照。分别于入院时及发病第3,7,14天四个时间点,采用ELISA法检测卒中患者血清CXCL12水平。结果 三个亚组患者在急性期4个时间点血清CXCL-12水平均高于对照组(F=29.523,31.690,38.962,22.365,均P<0.001),血清CXCL-12水平动态变化均表现为发病24 h内显著升高,发病第3天达到峰值,之后缓慢下降。多因素Logistic回归分析结果显示对于三个亚组,均表现为发病第7天血清CXCL-12升高与预后不良相关。结论缺血性卒中不同亚型患者急性期血清CXCL-12均显著升高,且血清CXCL-12过高可能提示患者预后不良。
Abstract:
Abstract:Objective To observe the dynamic change of serum CXCL-12 in patients with different subtypes of acute ischemic stroke.Methods 141 patients with acute ischemic stroke from January 2014 to June 2016 were recruited to participate in the study as stroke group.According to TOAST classification,they were divided into LAA group(52 cases),SAO group(54 cases)and CE group(35 cases).60 healthy physical examination patients in Affiliated Hospitd of Yan'an University physical examination centre in same time were selected as control group.Serum CXCL-12 of stroke patients were detected at admission,3th day,7th day and 14th day after stroke.Results Compared withthe control group,the serum CXCL-12 level at four different time during acutestage were higher in three subgroups.Serum CXCL-12 in patients of three stokesubgroups was significantly increase within 24 hour after stroke.And it wouldpeak at 3th day.Then,the level of serum CXCL-12 began to fall.Multivariate Logistics analysis showed that serum CXCL-12 level in patients with three different stroke subgroups at 7th day after stroke was the risk factor of poor prognosis.Conclusion For the patients with different subtypes of acute ischemic stroke,the serum CXCL-12 levels increased significantly.Moreover,the high level of serum CXCL-12 may correlate with poor prognosis.

参考文献/References:

[1] Goyal M,Demchuk AM,Menon BK,et al.Randomized assessment of rapid endovascular treatment of ischemic stroke[J].N Engl J Med,2015,372(11):1019-1030.
[2] Powers WJ,Derdeyn CP,Biller J,et al.2015 AHA/ASA focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment:a guideline for health care professionals from the American Heart Association/American Stroke Association[J].Stroke,2015,46(10):3020-3035.
[3] 张 钰,顾 艳,李俊霞,等.趋化因子CXCL12,CCL2,RANTES与早期流产的相关性[J].中华医学杂志,2012,92(1):9-11. Zhang Y,Gu Y,Li JX,et al.Correlations between chemokines CXCL12,CCL2,RANTES and early abortion[J].Natl Med J China,2012,92(1):9-11.
[4] 肖新兴,刘庆新,邹雪飞,等.急性脑梗死患者血浆CXCL12水平的改变及其对预后的影响[J].临床神经病学杂志,2015,28(2):91-94. Xiao XX,Liu QX,Zou XF,et al.Changes of plasma CXCL12 levels andtheir effects on the prognosis in acute cerebral infarction patients[J].Journal of Clinical Neurology,2015,28(2):91-94.
[5] Schutt RC,Burdick MD,Strieter RM,et al.Plasma CXCL12 levels as a predictor of future stroke[J].Stroke,2012,43(12):3382-3386.
[6] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志,2010,43(2):146-153. Write Team of Guidelines of Diagnosis and Treatment of Acute Ischemic Stroke,Cardiovascular Epidemiology group,Neurology Branch of Chinese MedicalAssociation.Chinese guidelines of diagnosis and treatment of acute ischemic stroke(2010)[J].Chinese Journal of Neurology,2010,43(2):146-153.
[7] Ruscher K,Kuric E,Liu Y,et al.Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke[J].J Cereb Blood Flow Metab,2013,33(8):1225-1234.
[8] Gu XL,Liu L,Lu XD,et al.Serum CXCL12 levels as a novel predictor of future stroke recurrence in patients with acute ischemic stroke[J].Mol Neurobiol,2016,53(5):2807-2814.
[9] 郑福利,党 淼,张淼芳,等.子宫内膜癌组织中趋化因子CXCL12及其受体CXCR4表达水平研究[J].现代检验医学杂志,2015,30(4):21-23,27. Zheng FL,Dang M,Zhang MF.et al.Expression of chemokine CXCL12 and its receptor CXCR4 in endometrial carcinoma tissues[J].Journal of Modern Laboratory Medicine,2015,30(4):21-23,27.
[10] Wang F,Yasuhara T,Shingo T,et al.Intravenous administrationof mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats:Focusing on neuroprotective effects of stromal cell-derived factor-1α[J].BMC Neurosci,2010,11(1):52.
[11] Wurster T,Tegtmeyer R,Borst O,et al.Platelet expression of stromal cell-derived factor-1 is associated with the degree of valvular aortic stenosis[J].PLoS One,2014,9(5):e97405.
[12] 肖新兴,刘庆新.趋化因子CXCL12在缺血性脑卒中的作用及其机制[J].中华脑科疾病与康复杂志(电子版),2014,4(3):45-48. Xiao XX,Liu QX.The role and mechanism of chemokine CXCL12 in ischemic stroke[J].Chinese Journal of Brain Diseases and Rehabilitatin(Electronic Edition),2014,4(3):45-48.
[13] Kim SJ,Moon GJ,Chang WH,et al.Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum:current evidence and study protocol for a randomized trial[J].Trials,2013,14(1):317.
[14] Cheng X,Lian YJ,Ma YQ,et al.Elevated serum levels of CXC chemokine ligand-12 are associated with unfavorable functional outcome and mortalityat 6-month follow-up in Chinese patients with acute ischemic stroke[J].MolNeurobiol,2017,54(2):895-903.
[15] Wang Y,Huang J,Li Y,et al.Roles of chemokine CXCL12 and its receptors in ischemic stroke[J].Curr Drug Targets,2012,13(2):166-172.
[16] Ghanem I,Riveiro ME,Paradis V,et al.Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis[J].Am J Transl Res,2014,6(4):340-352.

备注/Memo

备注/Memo:
基金项目:陕西省教育厅自然科学研究项目(2013JK0781)。 作者简介:林 芳(1980-),女,主治医师,研究方向:老年病神经方面的治疗,E-mail:linfang198009@163.com。
更新日期/Last Update: 1900-01-01